These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 17210705)
1. Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Dennis MS; Jin H; Dugger D; Yang R; McFarland L; Ogasawara A; Williams S; Cole MJ; Ross S; Schwall R Cancer Res; 2007 Jan; 67(1):254-61. PubMed ID: 17210705 [TBL] [Abstract][Full Text] [Related]
2. Development and preclinical studies of Lam K; Chan C; Reilly RM MAbs; 2017 Jan; 9(1):154-164. PubMed ID: 27813707 [TBL] [Abstract][Full Text] [Related]
3. Metal-Chelating Polymers (MCPs) with Zwitterionic Pendant Groups Complexed to Trastuzumab Exhibit Decreased Liver Accumulation Compared to Polyanionic MCP Immunoconjugates. Liu P; Boyle AJ; Lu Y; Adams J; Chi Y; Reilly RM; Winnik MA Biomacromolecules; 2015 Nov; 16(11):3613-23. PubMed ID: 26469142 [TBL] [Abstract][Full Text] [Related]
4. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments. Tang Y; Scollard D; Chen P; Wang J; Holloway C; Reilly RM Nucl Med Commun; 2005 May; 26(5):427-32. PubMed ID: 15838425 [TBL] [Abstract][Full Text] [Related]
5. MicroSPECT/CT imaging of co-expressed HER2 and EGFR on subcutaneous human tumor xenografts in athymic mice using ¹¹¹In-labeled bispecific radioimmunoconjugates. Razumienko E; Dryden L; Scollard D; Reilly RM Breast Cancer Res Treat; 2013 Apr; 138(3):709-18. PubMed ID: 23525982 [TBL] [Abstract][Full Text] [Related]
6. Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using (111)In-trastuzumab (Herceptin) Fab fragments. Tang Y; Wang J; Scollard DA; Mondal H; Holloway C; Kahn HJ; Reilly RM Nucl Med Biol; 2005 Jan; 32(1):51-8. PubMed ID: 15691661 [TBL] [Abstract][Full Text] [Related]
7. Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Olafsen T; Kenanova VE; Sundaresan G; Anderson AL; Crow D; Yazaki PJ; Li L; Press MF; Gambhir SS; Williams LE; Wong JY; Raubitschek AA; Shively JE; Wu AM Cancer Res; 2005 Jul; 65(13):5907-16. PubMed ID: 15994969 [TBL] [Abstract][Full Text] [Related]
8. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer. Chen KT; Lee TW; Lo JM Nucl Med Biol; 2009 May; 36(4):355-61. PubMed ID: 19423002 [TBL] [Abstract][Full Text] [Related]
9. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates. Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962 [TBL] [Abstract][Full Text] [Related]
10. A kit to prepare (111)In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer. Scollard DA; Chan C; Holloway CM; Reilly RM Nucl Med Biol; 2011 Jan; 38(1):129-36. PubMed ID: 21220136 [TBL] [Abstract][Full Text] [Related]
11. Generation of DOTA-conjugated antibody fragments for radioimmunoimaging. Smith-Jones PM; Solit DB Methods Enzymol; 2004; 386():262-75. PubMed ID: 15120256 [No Abstract] [Full Text] [Related]
12. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729 [TBL] [Abstract][Full Text] [Related]
13. Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials. Milenic DE; Wong KJ; Baidoo KE; Nayak TK; Regino CA; Garmestani K; Brechbiel MW MAbs; 2010; 2(5):550-64. PubMed ID: 20716957 [TBL] [Abstract][Full Text] [Related]
14. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates. Razumienko EJ; Scollard DA; Reilly RM J Nucl Med; 2012 Dec; 53(12):1943-50. PubMed ID: 23096164 [TBL] [Abstract][Full Text] [Related]
15. Uptake of radiolabelled herceptin by experimental mammary adenocarcinoma. Wiercioch R; Balcerczak E; Byszewska E; Mirowski M Nucl Med Rev Cent East Eur; 2003; 6(2):99-103. PubMed ID: 14737722 [TBL] [Abstract][Full Text] [Related]
16. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. Orlova A; Wållberg H; Stone-Elander S; Tolmachev V J Nucl Med; 2009 Mar; 50(3):417-25. PubMed ID: 19223403 [TBL] [Abstract][Full Text] [Related]
17. Comparison of biodistribution of 791T/36 monoclonal antibody and its Fab/c fragment in BALB/c mice and nude mice bearing human tumor xenografts. Demignot S; Pimm MV; Baldwin RW Cancer Res; 1990 May; 50(10):2936-42. PubMed ID: 2334894 [TBL] [Abstract][Full Text] [Related]
18. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Adams GP; Tai MS; McCartney JE; Marks JD; Stafford WF; Houston LL; Huston JS; Weiner LM Clin Cancer Res; 2006 Mar; 12(5):1599-605. PubMed ID: 16533787 [TBL] [Abstract][Full Text] [Related]
19. Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct. Kelly MP; Lee FT; Tahtis K; Power BE; Smyth FE; Brechbiel MW; Hudson PJ; Scott AM Cancer Biother Radiopharm; 2008 Aug; 23(4):411-23. PubMed ID: 18771345 [TBL] [Abstract][Full Text] [Related]